# A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-cost-effectiveness-analysis-of-trastuzumab-containing-treatment-sequences-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Vakaramoko Diaby,Hussain Alqhtani,Sascha van Boemmel-Wegmann,Ching-Yu Wang,Askal Ayalew Ali,Rajesh Balkrishnan,Yu Ko,Sofia Palacio,Gilberto Lopes |
| Citations | 16 |
| DOI | 10.1016/j.breast.2019.11.012 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.thebreastonline.com/article/S096097761931104X/pdf |
| OpenAlex ID | https://openalex.org/W2989987240 |
| PMID | 31805500 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Askal Ayalew Ali](https://scholariq.org/researchers/askal-ayalew-ali/)

## Paper journal

- [The Breast](https://scholariq.org/journals/the-breast/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.